The process of identifying promising small molecule drug candidates that target cancer checkpoints ... so they are unleashed ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

The process of identifying promising small molecule drug candidates that target cancer checkpoints may become faster and ...

The US Food and Drug Administration (FDA ... With “true game changers” — such as checkpoint inhibitors for melanoma and ...

Additionally, positive findings from trials like ADRIATIC (NCT03703297) and IMforte (NCT05091567) are further shaping ...

Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk localized, muscle-invasive disease, according to a new editorial.

Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk localized, muscle-invasive disease, according to an editorial published in ...

In July 2024, Checkpoint announced that the FDA accepted for review the resubmission of its BLA for cosibelimab as a complete response to the complete response letter (“CRL”) issued in December 2023 ...